Breaking News
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Got A Stimulus Check? These 2 ETFs Are Worthy Investments

By Investing.com (Tezcan Gecgil/Investing.com )ETFsMar 15, 2021 06:02
ca.investing.com/analysis/got-a-stimulus-check-these-2-etfs-are-worthy-investments-200455409
Got A Stimulus Check? These 2 ETFs Are Worthy Investments
By Investing.com (Tezcan Gecgil/Investing.com )   |  Mar 15, 2021 06:02
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

The U.S. government has started sending out the third round of direct stimulus checks to eligible Americans. For those readers who have decided to invest some or all of the stimulus payment, buying an exchange-traded fund (ETF) for the long-term could be a viable option.

Let’s assume an individual is now 30 and plans to invest $1,400 across several funds. S/he has 35 years to invest. The annual return is 8%, compounded once a year, at the start of the compounding period. At the end of 35 years, the total amount saved is close to $20,700. And if the annual return were 10%, the final amount goes over $39,000.

With that information, today's article introduces two ETFs that could appeal to a wide range of market participants.

1. SPDR S&P Biotech ETF

  • Current Price: $146.51
  • 52-week range: $62.94 - $174.79
  • Dividend Yield: 0.19%
  • Expense Ratio: 0.35%

The SPDR® S&P Biotech ETF (NYSE:XBI) gives access to 170 biotechnology stocks. Since its inception in January 2006, net assets have grown to $7.4 billion.


XBI Weekly
XBI Weekly

XBI tracks the S&P Biotechnology Select Industry, which is equal-weighted. We recently discussed how equal-weight ETFs might help diversify long-term portfolios. Around 15% of the fund is in the top ten companies, whose market capitalizations (caps) range from $650 million to $33.3 billion.

Recent statistics highlight:

“Biotech companies have revolutionized multiple sectors, most notably agriculture and medicine… The global biotechnology market value is expected to reach $727.1 billion by 2025. It takes an average of 12 years for an experimental drug to traverse from the laboratory setting to the patient.”

Put another way, it can be a long wait for investors to see significant gains as businesses work with regulatory authorities for approvals.

Clinical-stage immunology group Vir Biotechnology (NASDAQ:VIR), Ligand Pharmaceuticals (NASDAQ:LGND), which holds economic rights to a range of medicines, BioCryst Pharmaceuticals (NASDAQ:BCRX), which focuses on the treatment of rare diseases, clinical-stage vaccine company Novavax (NASDAQ:NVAX), and clinical-stage biopharma Agios Pharmaceuticals (NASDAQ:AGIO) top the names in the roster of the ETF.

In the past 12 months, XBI returned over 106% and hit an all-time high on Feb. 9. Since then, it has lost about 16%. Given the choppiness in broader markets, there could be further profit taking in the names that make up the fund.

The biotech space remains a high-growth area. However, it is also a volatile sector. In the case of an unsuccessful clinical trial or a regulatory hurdle, a biotech name could lose a substantial amount of value in a matter of days.

Therefore, exposure to a large range of biotech names via a diversified ETF could be appropriate for most retail portfolios. In the coming quarters, many of the companies in the fund are likely to grow significantly or even become takeover candidates. The record-low interest rate environment, coupled with advances we have seen in the biopharma space due to the pandemic, have put the industry in the limelight.

2. ARK Israel Innovative Technology ETF

  • Current Price: $32.82
  • 52-week range: $14.00 - $38.77
  • Dividend Yield: 1.45%
  • Expense Ratio: 0.49%

The ARK Israel Innovative Technology ETF (NYSE:IZRL) invests in exchange-listed companies incorporated and/or domiciled in Israel. The fund started trading in December 2017, and net assets stand at $76 million.

According to Deloitte:

"With over 6,000 active startups and an economy dominated by industrial high-tech and entrepreneurship, Israel certainly earned its nickname 'The Startup Nation'."

The Global Innovation Index (GII) puts Israel at number 13 among 131 nations. The country regularly has a high "innovation" ranking in other similar indices, such as the Bloomberg Index Of Innovative Countries or the World Economic Forum's Global Competitiveness Report.

IZRL Weekly
IZRL Weekly

IZRL, which has 43 stocks, tracks the ARK Israeli Innovation Index, an equal-weight index rebalanced quarterly. As far as sectors are concerned, information technology tops the list with 50.6%, followed by health care (23.2%) and communication services (11.3%).

About two-thirds of the fund is in small-cap businesses—which the fund defines as those with market-caps of $300 million to $2 billion. Close to 16% of the fund is also in mid-caps—those stocks with market-caps of $2 billion to $10 billion.

Among the leading names in the ETF are digital advertising platform Perion Network (TASE:PERI) (NASDAQ:PERI), Gilat (TASE:GILT) (NASDAQ:GILT), which specializes in satellite networking technology, medical device group Intercure (TASE:INCR), whose Canndoc unit produces medical-grade cannabis, E&M (TASE:EMCO) that specializes in cloud, information systems, and data-center technologies, and InMode (NASDAQ:INMD) which develops minimally-invasive surgical and medical treatment solutions, such as those used in cosmetic procedures.

Over the past year, IZRL is up about 107% and hit a record high in early February. However, since then, the fund has lost about 33% in value. Those long-term investors who believe the innovative and entrepreneurial nature of these businesses will continue to create shareholder value might consider buying the fund around these levels.

Got A Stimulus Check? These 2 ETFs Are Worthy Investments
 

Related Articles

Got A Stimulus Check? These 2 ETFs Are Worthy Investments

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email